Florida Cancer Specialists & Research Institute

Florida Cancer Specialists & Research Institute welcomes Colleen Lewis, MSN, ANP-BC, AOCNP to its senior leadership team as Vice President of Nursing and Research.

Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on June 16, 2022 to celebrate the opening of a new clinical site in Kissimmee, FL.

A member of Florida Cancer Specialists & Research Institute, LLC, has been selected as a recipient of the 40 Under 40 in Cancer Award.

Florida Cancer Specialists & Research Institute continues to expand clinical trial opportunities for cancer patients close to home.

The Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.

Florida Cancer Specialists & Research Institute, LLC's oral oncolytic specialty pharmacy, Rx To Go, has earned URAC accreditation for Specialty Pharmacy.

By advocating for mental health services and providing education, those at Florida Cancer Specialists can assist patients and each other in improving well-being and quality of life.

Ibrahim Sadek, MD, has joined Florida Cancer Specialists & Research Institute.

Florida Cancer Specialists & Research Institute, LLS announces Martin Dietrich, MD, PhD, as the 2022 Man of the Year by the Orlando Chapter of the Leukemia & Lymphoma Society.

Richard McDonough, MD, joins the Florida Cancer Specialists & Research Institute.

Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib had comparable overall survival outcomes to those given the standard dose.

Florida Cancer Specialists & Research Institute clinicians and leaders shared the latest advances in oncology pharmacy operations and dispensing practices at the National Community Oncology Dispensing Association 2022.

Florida Cancer Specialists & Research Institute, LLC has opened a new state-of-the-art facility in Fort Myers to provide comprehensive treatments and a variety of services to adults with cancer and other diseases.

Florida Cancer Specialists & Research Institute announced a dynamic new partnership that will help prepare a diverse population of students for job opportunities and support them while they continue their education.

Medical oncologist Michael Diaz, MD, President & Managing Physician of Florida Cancer Specialists & Research Institute, LLC is the recipient of the Florida Society of Clinical Oncology Dorothy Green Phillips Legacy Award 2022.

More than FCS 40 nurses were nominated by their peers and fellow team members for their superior quality of oncology nursing and leadership capabilities.

Florida Cancer Specialists & Research Institute sites and site worldwide are now recruiting patients for the PROPHETIC study.

Oncologists from Florida Cancer Specialists & Research Institute recently participated in the FLASCO Fellow & Resident Educational Training Program.

Over the past 3 decades, cancer treatment options have increased immensely, according to Florida Cancer Specialists & Research Institute.

Oncologists at FCS, Lucio N. Gordan, MD and Ivor Percent, MD have published findings from the CheckMate 920 clinical trial.

Florida Cancer Specialists shares profile of Katy Phelan, PhD, the director of the organizations Genetics Laboratory.

During a live virtual event, Lowell Hart, MD, discussed the findings of the monarchE trial of abemaciclib in high-risk patients with early breast cancer.

Specially trained professionals working together are required to ensure that oncologic pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.

Florida Cancer Specialist & Research Institute is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state.

The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances.

In this companion article, Dr. Lowell L. Hart shares key insights into how trilaciclib has begun to impact the management of chemotherapy-induced myelosuppression in patients with SCLC.

During a live virtual event, Lowell Hart, MD, discussed the results of the monarchE trial of abemaciclib in patients with node-positive, hormone receptor–positive, HER2-negative, high-risk early breast cancer.

A medical oncologist, Shalin R. Shah, DO, is the newest member of the American Oncology Network's executive board.

Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.

In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.